To include your compound in the COVID-19 Resource Center, submit it here.

Blueprint reports Phase I data for avapritinib in systemic mastocytosis

Blueprint Medicines Corp. (NASDAQ:BPMC) reported its lead candidate, avapritinib (formerly BLU-285), led to an overall response rate (ORR) of 72% in 18 evaluable patients with advanced systemic mastocytosis (SM) in a Phase I trial.

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE